ArticleActa pharmacologica Sinica2026
BMAL1 silencing as a promising chemosensitizing strategy for triple-negative breast cancer.
Article in Acta pharmacologica Sinica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The circadian-melatonin axis in breast cancer metastasis: molecular mechanisms, organ-specific metastatic niches, and therapeutic opportunities.Frontiers in endocrinology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Circadian genes are closely associated with tumor development and its sensitivity to chemotherapeutic agents. In triple-negative breast cancer (TNBC), the core circadian gene BMAL1 exhibits an aberrant expression pattern, but its mechanism of influencing TNBC chemosensitivity remains unknown. In this study, we demonstrate that BMAL1 acts as an oncogene in TNBC. Using BMAL1 siRNA-loaded lipid nanoparticles (LNPs), we effectively silenced BMAL1 expression both in vitro and in vivo, resulting in enhanced apoptosis and reduced proliferation of TNBC cells. Notably, BMAL1 suppression following chemotherapy-induced DNA damage impairs the RPA-ATR-CHK1 DNA repair axis, leading to S-phase arrest and accumulation of unrepaired DNA damage. This synergistically increases the sensitivity of TNBC cells to etoposide. Our findings reveal BMAL1 as a promising therapeutic target and support the potential of silencing BMAL1 with siRNA as a neoadjuvant strategy in combination with chemotherapeutic agents for the treatment of TNBC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.